Trial Name: DO410
A National Web-Based Randomized Phase III
Study of Erlotinib or Placebo Following Concurrent Docetaxel,
Carboplatin and Thoracic Radiotherapy in Patients with Inoperable
Stage III Non-Small Cell Lung Cancer
Trial
Description:
The objective of this trial is to determine
whether taking erlotinib (Tarceva) following treatment with
chemotherapy and radiation therapy for inoperable stage III,
non-small cell lung cancer is more effective than chemotherapy and
radiation therapy alone.
Treatment
Plan:
Patients will be randomized to one of two
treatment arms:
1. Arm A - chemotherapy, radiation therapy
plus tarceva
2. Arm B - chemotherapy, radiation therapy plus placebo
Patients:
- Newly diagnosed inoperable stage III
non-small cell lung cancer with no evidence of metastatic
disease
- No brain metastases
- No previous chemotherapy or radiation therapy for lung
cancer
- Lab tests, a current physical exam and medical history must
meet study specific criteria
This is a brief overview
of this clinical trial and only selected eligibility criteria are
listed. If you are interested in receiving more information to see
if you are eligible to participate in this study, please
contact:
Mercy General
Hospital
Rhoda Pineda at (916) 453-4651, or e-mail
rpineda@chw.edu
Mercy San Juan
Medical Center
Margaret Murphy at
(916) 537-5109, or e-mail margaret.murphy2@chw.edu
